Drug intelligence / Profile preview

Micrococcus luteus Q24

Development stage: Unknown
Lead developer: BLIS Technologies
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Topical

Overview

Micrococcus luteus Q24 (also known as BLIS Q24) is a probiotic bacterial strain developed by BLIS Technologies for topical application to the skin and scalp. As a live biotherapeutic product, it is intended to colonize the human skin microbiome, potentially improving skin quality and providing a protective barrier against dysbiosis. The strain is being evaluated in various topical formats, including serums and balms, for its ability to establish a stable population on the face, scalp, and forearms of healthy adults. Clinical trials have focused on assessing changes to the local skin microbiome and improvements in skin quality parameters following application.

Other names: M. luteus Q24

Beyond the preview

Go deeper on Micrococcus luteus Q24.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Micrococcus luteus Q24.

Explore the full profile